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Effective antibody responses provide crucial immunity against influenza virus infection. The hemagglutinin (HA)
protein is the major target of protective antibody responses induced by viral infection and by vaccination with both
inactivated and live-attenuated flu vaccines, but knowledge about the optimal designs of protective HA antigens
from different flu serotypes is still limited. In this study, we have significantly improved the immunogenicity of
HA-expressing DNA vaccines by using codon-optimized HA sequences for either an H1 serotype (A/NewCal/20/99)
or an H3 serotype (A/Panama/2007/99) human influenza A virus and then used these constructs as model antigens
to identify the optimal HA antigen designs to elicit high-level protective antibody responses. Two forms of HA
antigen, a wild-type, full-length HA and a secreted form with transmembrane (TM) domain-truncated HA, were
produced. Both forms of HA DNA vaccines, from either H1 or H3 serotypes, were able to elicit high levels of
HA-specific immunoglobulin G responses in immunized rabbits as measured by enzyme-linked immunosorbent
assay. Interestingly, the abilities of H1 HA and H3 HA antigens to elicit hemagglutination inhibition (HI) and
neutralizing antibody (NAb) responses differ. For the H1 HA antigens, the full-length HA induced significantly
higher HI and NAb responses than did the TM-truncated HA. For the H3 HA antigen, both the full-length HA and
TM-truncated HA induced high levels of HI and NAb responses. These data indicate that H1 and H3 antigens have
different expression requirements for the induction of an optimal protective antibody response and that the
structure integrity of HA antigens is critical for eliciting type-specific protective antibody responses. Our findings
will have an important impact on future subunit-based flu vaccine development.
Influenza virus infection continues to be a major public
health threat to human society and animals. Influenza A vi-
ruses are the most important because they cause both epidemic
and pandemic flu in humans (37). Influenza A viruses have a
wide natural host range, including humans and other animals,
such as birds, pigs, and horses, and they have a high degree of
genetic and antigenic variability (37). Seasonal or epidemic flu
infections produce high morbidity and mortality, and the po-
tential for pandemic flu with influenza viruses containing an-
tigenic determinants from an avian source has become a new
emerging threat to the worldwide human population. The best
option for reducing the impact of influenza virus infection to
humans is vaccination (36).
The major form of current human influenza virus vaccines is
the traditional trivalent inactivated influenza vaccine (TIV)
that incorporates currently circulating viral strains in humans:
an H1 subtype and an H3 subtype of influenza A viruses plus
an influenza B virus. Recently developed cold-adapted live
influenza virus vaccines are more effective than TIV for induc-
ing local immunity and cell-mediated immunity which may be
associated with a longer-lasting and more cross-protective im-
munity than that which is elicited by TIV (5). Because some of
the new target influenza viruses (e.g., H5 and H7 avian flu
viruses) grow poorly in eggs, a new technology called reverse
genetics has been developed to generate high-growth reassor-
tants (8, 12, 14, 31, 32, 43) that combine viral genes from the
high-growth-yield laboratory strain of influenza A virus A/PR/
8/34 with the genes encoding the antigenic glycoproteins of the
target avian viral strains. The hemagglutinin (HA) gene is
modified to eliminate high virulence associated with the cleav-
age site of the HA, allowing the virus to replicate to high titers
in eggs (15, 24, 26, 34, 35, 48, 49). However, this technology
advancement did not change the fact that large stocks of vac-
cine viruses still have to be produced for the inactivation and
purification of protective HA antigens. This process is cum-
bersome, lengthy, and costly. Moreover, inactivated pandemic
flu vaccines appear to be poorly immunogenic and require high
doses to elicit protective antibody responses in humans (33,
51). At the same time, subunit-based flu vaccines, such as those
based on recombinant HA antigens, have not been very suc-
cessful and the reason for such failure is not very clear. In early
studies, HA-expressing DNA vaccines, while effective for pro-
tecting animals from lethal challenge, were unable to elicit
detectable HA-specific, protective antibody responses before
challenge (9). This greatly limited the potential for DNA vac-
cines to serve as a useful tool to study antigen design leading to
optimized flu vaccines.
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In the past decade, important new discoveries have been
made to further improve the efficacy of DNA vaccines. Opti-
mized codon usage is one such improvement, and it has been
effective for increasing the overall antigen production and im-
munogenicity of DNA vaccines (54). In the current study, we
tested whether codon-optimized, HA-expressing DNA vac-
cines will be able to elicit high-level, protective antibody re-
sponses prior to viral challenge. Furthermore, we used such
improved HA DNA vaccines to initiate studies on the optimal
design of HA antigens for the induction of best protective
antibody responses, including their use in bivalent formula-
tions against more than one serotype of influenza A viruses.
Our data suggested that codon optimization is effective for
improving anti-HA antibody responses in both mouse and rab-
bit models. Interestingly, HA antigens from H1 or H3 sero-
types had different preferred antigen designs for generating
protective antibodies. Therefore, our results established an
important technology platform to identify and optimize the
most protective HA antigen designs. Such information not only
is important for the selection and modification of HA antigens
to be incorporated as part of inactivated or live-attenuated flu
vaccines against emerging endemic or pandemic flu viruses but
also opens new opportunities for the development of subunit-
based flu vaccines.
MATERIALS AND METHODS
Construction of codon-optimized HA DNA vaccine constructs. The codon
usage of HA genes from influenza A human viruses A/NewCal/20/99 (H1N1) and
A/Panama/2007/99 (H3N2) was analyzed with MacVector 7.2 software against the
codon preference of Homo sapiens. The less optimal codons in HA genes were
changed to the preferred codons of mammalian systems to promote higher expres-
sions of the HA proteins. The codon optimization strategy was not limited to the
change of codons for mammalian usage. Sequence optimization was also performed
to make the mRNA more stable and the gene more favorable for the transcriptional
and translational process. During sequence optimization, the following cis-acting
sequence motifs were avoided: internal TATA boxes, chi sites, and ribosomal entry
sites; AT-rich or GC-rich sequence stretches; ARE, INS, and CRS sequence ele-
ments; cryptic splice donor and acceptor sites; and branch points. Despite such
DNA-level sequence changes, the final codon-optimized H1 or H3 HA DNA se-
quences still produced the same HA amino acid (aa) sequences as those in the
original flu viruses. These codon-optimized HA genes were chemically synthesized
by Geneart (Regensburg, Germany), with added restriction enzyme sites of PstI and
BamHI for subcloning purposes immediately upstream of the start codon and down-
stream of the stop codon, respectively.
For either H1 or H3 HA DNA vaccines, two versions of codon-optimized HA
gene inserts were cloned into DNA vaccine vector pSW3891 (53), a derivative of
pJW4303 (27), using a cytomegalovirus immediate-early promoter. For the first
version, full-length HA gene inserts (H1-HA and H3-HA, 565 aa for both
inserts) with their natural HA leader sequences were subcloned individually into
the pSW3891 vector at the PstI and BamHI sites. For the second version, a
transmembrane (TM)- and cytoplasmic region-truncated form of HA (H1-
HA.dTM, aa 23 to 527, or H3-HA-dTM, aa 21 to 527) was PCR amplified from
the full-length, codon-optimized H1 or H3 HA genes by using the following
primers: H1-HA-opt-1 (5 GTCGCTCCGCTAGCGGCTACCACGCCAACAA
CAGC 3) and H1-HA-opt-2 (5 AGTCACGGATCCTCACTGGTACACGCC
CATGCTCTC 3) for H1-HA.dTM or H3-HA-opt-1 (5 GTCGCTCCGCTAG
CGGCAACGACAACAGCACCGCCACC 3) and H3-HA-opt-2 (5 AGTCAC
GGATCCTCAATCCTTGTAGCCGCTCTTCAG 3) for H3-HA.dTM. Both
HA.dTM gene inserts were individually cloned into the pSW3891 vector at the
NheI and BamHI sites downstream of a human tissue plasminogen activator
(tPA) leader sequence substituting for the natural HA leader sequence. Each
individual DNA vaccine plasmid was prepared from Escherichia coli (HB101
strain) with a Mega purification kit (QIAGEN, Valencia, CA) for both in vitro
transfection and in vivo animal immunization studies.
DNA immunization of New Zealand White (NZW) rabbits and BALB/c mice.
NZW rabbits (2 kg of body weight) were purchased from Millbrook Breeding
Labs (Amherst, MA), and BALB/c mice (6 to 8 weeks old) were purchased from
Taconic Farms (Germantown, NY) for immunogenicity studies. Both rabbits and
mice were housed by the Department of Animal Medicine at the University of
Massachusetts Medical School in accordance with IACUC-approved protocol.
The rabbits were immunized with a Helios gene gun (Bio-Rad) at the shaved
abdominal skin as previously reported (55). For each immunization, a total of 36
g of HA DNA vaccine plasmid or vector control plasmid was delivered. In the
bivalent H1 and H3 HA DNA vaccine study, 18 g of each HA DNA vaccine
plasmid was delivered. For the mouse immunogenicity study, 100 g of HA DNA
vaccine plasmid or vector control plasmid was delivered at each immunization by
intramuscular injection. Immunizations for both rabbits and mice were given at
weeks 0, 2, 4, and 8. For the study of HA-specific antibody responses, serum
samples were taken prior to the first immunization and 2 weeks after each
immunization.
Western blot analysis of in vitro-expressed HA antigens. Transient expression
of the HA antigens from various HA DNA vaccine constructs was verified by
Western blot analysis. HA DNA vaccine constructs were first transfected into the
human embryonic kidney 293T cells by using the calcium phosphate precipitation
method. Briefly, 2  106 293T cells at 50% confluence in a 60-mm dish were
transfected with 10 g of plasmid DNA and harvested 72 h later. Equal amounts
of each transiently expressed HA antigen (10 ng of protein) were loaded for
sodium dodecyl sulfate-polyacrylamide gel electrophoresis under denatured con-
ditions and then transferred onto polyvinylidene difluoride membranes (Bio-
Rad, Hercules, CA). After being blocked overnight at 4°C in blocking buffer
(0.2% I-block, 0.1% Tween 20 in 1 phosphate-buffered saline [PBS]), the
membranes were incubated with a 1:500 dilution of rabbit sera immunized with
HA DNA vaccines for 30 min, followed by washes. Then the membranes were
incubated with alkaline phosphatase-conjugated goat anti-rabbit immunoglobu-
lin G (IgG) at a 1:5,000 dilution for 30 min. Following washes, the signals were
detected by using a chemiluminescence-based Western-Light kit (Tropix,
Bedford, MA).
ELISA. An enzyme-linked immunosorbent assay (ELISA) was conducted to
measure the HA-specific antibody (IgG) responses in immunized rabbits and
mice. The 96-well, flat-bottomed plates were coated with 100 l of concanavalin
A (50 g/ml) for 1 h at room temperature and washed five times with PBS
containing 0.1% Triton X-100. Subsequently, the plates were incubated over-
night at 4°C with 100 l of transiently expressed HA antigen at 1 g/ml. After
being washed five times as above, the plates were blocked with 200 l/well of
blocking buffer (5% nonfat dry milk, 4% whey, 0.5% Tween 20 in PBS at pH 7.2)
for 1 h. After five washes, 100 l of serially diluted rabbit or mouse serum was
added in duplicate wells and incubated for 1 h. After another set of washes, the
plates were incubated for 1 h at 37°C with 100 l of biotinylated anti-rabbit or
anti-mouse IgG (Vector Laboratories, Burlingame, CA) diluted 1:1,000 in whey
dilution buffer (4% whey, 0.5% Tween 20 in PBS). Then, 100 l of horseradish
peroxidase-conjugated streptavidin (Vector Laboratories) diluted 1:2,000 in
whey buffer was added to each well and incubated for 1 h. After the final washing,
the plates were developed with a 3,3,5,5-tetramethylbenzidine solution at 100
l per well (Sigma, St. Louis, MO) for 3.5 min. The reactions were stopped by
adding 25 l of 2 M H2SO4, and the plates were read at an optical density of 450
nm. The end titer was determined as the highest serum dilution that had an
optical density reading more than twice that of the negative control serum.
Preparation of the influenza A virus stocks. The human influenza A viruses
A/NewCaledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and A/Moscow/
22/99 (H3N2) were obtained from the CDC in Atlanta, Georgia. The A/NewCal/
20/99 virus has constituted the H1N1 component of the licensed human flu
vaccine since the period from 2000 to 2005. Either of the two H3N2 viruses was
the basis of the H3N2 component of the licensed human flu vaccine from 2000
to 2001 and 2003 to 2004. These viruses were cultured in the allantoic cavities of
10-day-old embryonated hen eggs and incubated for 2 days at 37°C. The allantoic
fluid was collected and stored at 80°C. The viruses were titrated in Madin-
Darby canine kidney (MDCK) cell cultures to determine the PFU per milliliter.
Protective antibody assays. Both hemagglutination inhibition (HI) and neu-
tralizing antibody (NAb) responses were measured. Three human influenza A
viruses were used in these assays: A/NewCal/20/99, A/Panama/2007/99, and
A/Moscow/22/99.
Sera were treated with receptor-destroying enzyme (RDE; Sigma-Aldrich, St.
Louis, MO) as described elsewhere (19). The lyophilized product was reconsti-
tuted with 5 ml sterile distilled water, diluted with 95 ml calcium saline (pH 7.2),
aliquoted, and stored at 20°C. RDE was combined with each serum sample in
a 4:1 ratio (0.2 ml RDE to 0.05 ml serum) and incubated overnight at 37°C.
Following the overnight incubation, 3 volumes (0.15 ml) of 2.5% sodium citrate
was added to each sample and incubated for 30 min at 56°C to inactivate the
remaining RDE. Finally, we added 2 volumes (0.1 ml) of PBS to raise the starting
serum dilution to 1:10.
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HI assays. HI assays were performed by standard methods (19). Briefly, 25 l
of each influenza virus strain with an HA titer of 8 HA units was mixed with 25
l of twofold dilutions of the specific RDE-treated serum in PBS in V-bottomed
96-well plates. After 30 min of incubation at room temperature, 50 l of 0.5%
chicken erythrocytes was added to the mixtures. The plates were kept at 4°C until
a positive hemagglutination was developed in non-serum-containing control
wells. The HI titer was defined as the highest dilution of the serum able to inhibit
hemagglutination.
Microneutralization assays. Titers of neutralizing antibodies were determined
essentially as described previously (28). In brief, 50 l of influenza virus con-
taining 100 PFU was incubated with 50 l of twofold dilutions of the specific
RDE-treated serum for 1 h at room temperature in a 96-well plate containing an
MDCK cell monolayer. After the incubation, the virus-serum samples were
removed from the wells. The cells were incubated at 37°C for 2 days in minimal
essential medium-bovine albumin supplemented with 1 g/ml of tosylsulfonyl
phenylalanyl chloromethyl ketone trypsin in the presence of twofold dilutions of
the specific RDE-treated serum. The microneutralization titer was defined as the
highest dilution of serum that neutralized 100 PFU of virus in MDCK cell
cultures (as detected by negative hemagglutination).
Statistical analysis. The Student t test was used to analyze the differences
between animal immunization groups regarding HA-specific binding antibody
responses as measured by ELISA, HI antibody titers, and neutralization antibody
titers. A P value of less than 0.05 was considered significant.
RESULTS
Codon-optimized HA DNA vaccine was able to achieve bet-
ter antigen expression and immunogenicity than was the wild-
type HA DNA vaccine. In order to improve the flu HA antigen
expression in mammalian cells and potentially the immunoge-
nicity of HA DNA vaccines, a codon-optimized HA gene from
influenza A/NewCal/20/99 virus (H1 serotype) was chemically
synthesized. During this process, the codon usage of HA amino
acids was changed to those preferred for expression in mam-
malian cells but the original flu HA amino acid sequences were
not altered. Figure 1A depicted the codon preference changes
between the wild-type HA gene and the codon-optimized HA
gene as analyzed by the MacVector software. Table 1 summa-
rized the percentage of codon usage before and after sequence
optimization. Both the wild-type and codon-optimized H1 HA
genes were then cloned individually into the DNA vaccine
vector pSW3891 to form two DNA vaccine plasmids, H1 HA
wild type (H1-HA.wt) and H1 HA optimized (H1-HA.opt),
respectively. They were transfected into 293T cells, and their
FIG. 1. A. Schematic diagram of influenza A H1 HA gene with HA1 and HA2 domains. The coding preferences of wild-type (H1-HA.wt) and
codon-optimized (H1-HA.opt) H1 HA genes were analyzed using the computer software MacVector. Plots with values above 1.0 indicate bias
toward codons more frequently used in mammalian systems, whereas plots below 1.0 indicate less preferred codons in mammalian systems.
(B) Western blot analysis of HA expression from either wild-type (wt) or codon-optimized (opt) H1-HA DNA vaccines in lysates of transiently
transfected 293T cells. Lysates from cells transfected with empty DNA vector pSW3891 without HA antigen insert were included as a negative
control. (C) Quantification of HA expression from either wild-type (wt) or codon-optimized (opt) H1-HA DNA vaccines by densitometry. The
relative amounts of HA antigens were measured by scanning HA-specific bands on Western blots by using an image processing system (Fujix
Pictrography 3000, Science Lab 2003, Image Gauge 4.22). The measured AU showed the geometric means of four independent assays. Error bars
indicate standard deviations.
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expression in mammalian cells was examined. As shown by
Western blot analysis (Fig. 1B and 1C), the H1-HA.opt con-
struct was able to achieve a higher level of expression than that
of the H1-HA.wt construct.
The relative immunogenicity between the wild-type and
codon-optimized H1 HA DNA vaccines was then studied in
rabbit and mouse models. In a pilot rabbit experiment, the
codon-optimized H1 HA DNA vaccine was able to elicit high-
level anti-HA antibody responses after only two DNA immu-
nizations, but for the wild-type H1 HA DNA vaccine, three to
four immunizations were required to elicit good but still lower
levels of anti-HA antibody response (Fig. 2A). Even after
multiple DNA-boosting immunizations, the peak-level anti-HA
antibody response elicited by the wild-type HA DNA vaccine
was still lower than that of the codon-optimized HA DNA
vaccine (Fig. 2B). A similar study was conducted in mice with
increased group size (10 animals per group). The geometric
mean titer for the codon-optimized HA DNA vaccine group
was significantly better than that of the wild-type HA DNA
vaccine group (P  0.001) (Fig. 2C). Therefore, our data
proved that codon optimization was effective for improving the
immunogenicity of flu HA DNA vaccine.
The cleavage of H1 and H3 HA proteins was affected by the
forms of HA antigens. Based on the above results, an addi-
tional codon-optimized HA gene from the H3 serotype flu
isolate A/Panama/2007/99 was chemically synthesized. Fur-
thermore, both codon-optimized H1 and H3 HA genes were
modified to produce two different forms of HA gene inserts
(Fig. 3A). One version, the H1-HA and H3-HA insert, coded
for the full-length HA proteins, including the natural HA pro-
tein leader sequences. The other design, H1-HA.dTM and
H3-HA.dTM insert, coded for only the extracellular portion of
the HA antigen. The TM and downstream cytoplasmic regions
were deleted. The natural leader of HA protein was also re-
placed by a tPA leader sequence based on the previous finding
that a tPA leader was highly effective in expressing secreted
proteins in mammalian cells for DNA vaccines (40, 54, 55).
The end products of HA.dTM constructs include the entire
HA1 domain and the extracellular portion of the HA2 domain
(Fig. 3A). The designation of HA1 and HA2 was based on the
TABLE 1. Codon usage of H1 HA wild-type and codon-optimized genesa
Amino
acid Codon
HA coding seq. Amino
acid Codon
HA coding seq.
wt opt wt opt
Ala GCT 19 0
GCC 38 100 Leu TTA 14 0
GCA 31 0 TTG 24 0
GCG 12 0 CTT 10 2
CTC 2 0
Arg CGT 0 0 CTA 21 0
CGC 0 0 CTG 29 98
CGA 0 0
CGG 0 47 Lys AAA 69 19
AGA 58 53 AAG 31 81
AGG 42 0
Pro CCT 24 5
Asn AAT 57 11 CCC 14 95
AAC 43 89 CCA 57 0
CCG 5 0
Asp GAT 56 17
GAC 44 83 Phe TTT 45 0
TTC 55 100
Cys TGT 69 19
TGC 31 81 Ser TCT 15 4
TCC 23 10
Gln CAA 63 0 TCA 27 0
CAG 37 100 TCG 0 0
AGT 18 0
Glu GAA 65 12 AGC 17 86
GAG 35 88
The ACT 26 0
Gly GGT 14 0 ACC 16 90
GGC 9 89 ACA 55 10
GGA 47 9 ACG 3 0
GGG 30 2
Tyr TAT 70 7
His CAT 57 0 TAC 30 93
CAC 43 100
Val GTT 20 0
Ile ATT 34 6 GTC 22 0
ATC 25 94 GTA 36 0
ATA 41 0 GTG 22 100
a The frequencies (%) of the individual codons are shown for each of the degenerately encoded amino acids. The most prevalent codon is shown in bold. seq.,
sequence.
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known cleavage sites (Q/E-X-R) for influenza HA proteins of
H1 and H3 serotypes (45).
The expression of HA antigens by the above-mentioned
different forms of HA DNA vaccines was assessed by their
transient transfection in 293T cells and Western blot analysis.
Regardless of H1 or H3 serotypes, all four HA DNA vaccine
constructs had good expressions of HA proteins (Fig. 3B). An
interesting finding was that the HA proteins expressed from
the H1-HA, H1-HA.dTM, and H3-HA.dTM inserts were in
mainly the noncleaved form, while the HA protein expressed
from the H3-HA insert was in the form of cleaved HA prod-
ucts of HA1 and HA2 subunits (Fig. 3B). Both H1 and H3 HA
proteins expressed from our DNA vaccines were N-glyco-
sylated as confirmed by the treatment of PNGase-F, which
removed the glycosylation and led to lower-molecular-weight
HA proteins (data not shown).
The full-length HA antigens, encoded by the H1-HA and
H3-HA DNA vaccines, were expressed mainly in cell-associ-
ated form, while truncation of the C-terminal segment, includ-
ing the removal of the TM domain (the H1-HA.dTM and
H3-HA.dTM DNA vaccines), was highly effective for produc-
ing more secreted HA antigen than did the full-length HA
design for both H1 and H3 serotypes (Fig. 3C). However, the
abilities of these DNA vaccines to elicit anti-HA antibody
responses were very similar (see below).
The immunogenicity of various forms of H1 and H3 HA
DNA vaccines. NZW rabbits were immunized with various
forms of codon-optimized H1 and H3 HA DNA vaccines with
a gene gun. Sera were collected 2 weeks after the fourth im-
munization to measure the peak-level antibody responses.
High-level anti-HA IgG responses were elicited with all four
HA DNA vaccines, and they were generally H1 or H3 type
specific (Fig. 4). Rabbit sera immunized with H1-HA or H1-
HA.dTM DNA vaccines recognized the H1 serotype HA an-
tigen almost exclusively. On the other hand, rabbit sera immu-
nized with H3-HA or H3-HA.dTM DNA vaccines mainly
recognized H3 serotype HA antigen but also had low-level
cross-reactivity against the H1 serotype HA antigen (Fig. 4).
There was no difference in the peak-level anti-HA antibody
responses between the full-length and TM-truncated HA an-
tigens (Fig. 4), although the HA.dTM DNA vaccines induced
a quicker rise of antibody responses than did the full-length
HA designs (data not shown).
High-level HI antibody responses induced by HA DNA vac-
cines. The functional activities of the anti-HA rabbit immune
sera were investigated by determining the HI antibody titers
against H1 or H3 influenza viruses. It was interesting to find
that, for H1 serotype HA DNA vaccines, the full-length HA
antigen elicited higher HI antibody titers against the autolo-
gous H1N1 virus A/NewCal/20/99 than did the TM region-
truncated HA.dTM antigen (Fig. 5A) (P  0.05). In contrast,
for H3 DNA vaccines, both the full-length and the TM-trun-
cated HA antigens were equally effective in inducing high HI
FIG. 2. Serum anti-HA IgG antibody responses induced with the
vaccinations with either H1-HA.wt or H1-HA.opt DNA vaccines in
NZW rabbits (A and B) and BALB/c mice (C) as measured by ELISA.
(A) Temporal anti-HA IgG responses in rabbits measured at a 1:5,000
serum dilution. The arrows indicate the time of gene gun-mediated
DNA immunizations. Animals R#316 and R#317 received H1-HA.wt
DNA vaccine, while R#381 and R#382 received H1-HA.opt DNA
vaccine. OD450, optical density at 450 nm. (B) End titers of serum
anti-HA IgG responses at 2 weeks after the fourth DNA immunization
from the same rabbits as shown in panel A. (C) End titers of serum
anti-HA IgG responses in BALB/c mice at 2 weeks after the fourth
DNA immunization. Animals received either H1-HA.wt or H1-
HA.opt DNA vaccines by intramuscular inoculation. Data shown are
the geometric mean titers of 10 mice in each group with standard
deviations (error bars).
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antibody titers against the autologous H3N2 virus A/Panama/
2007/99 (Fig. 5B) and a similar H3N2 virus A/Moscow/10/99
(data not shown). The HI activities in immunized rabbit sera
were highly specific for expected flu serotypes, i.e., rabbit sera
immunized with the H1-HA antigens did not show significant
HI titers against the H3 virus and the H3-HA antigen-immu-
nized rabbit sera did not show high HI activities against the H1
virus (Fig. 5). The HI titers for control rabbits immunized twice
with the licensed inactivated human flu vaccine (Fluzone) were
at levels in the 1:200 to 1:300 range (data not shown).
Virus-neutralizing antibody responses induced by H1 and
H3 HA DNA vaccines. The protective antibody responses in-
duced by different forms of HA DNA vaccines were further
confirmed by a microneutralization assay. The patterns of neu-
tralizing antibody activities for different forms of HA DNA
vaccines were similar to that shown by the HI assay. For H1
FIG. 3. (A) Schematic diagram of various HA gene inserts used in codon-optimized H1 (A/New Caledonia/20/99) and H3 (A/Panama/2007/99)
HA DNA vaccines, including the full-length HA antigens (H1-HA or H3-HA) and the transmembrane/cytoplasmic region-truncated HA antigens
(H1-HA.dTM or H3-HA.dTM) where a human tPA leader also replaced the natural HA leader sequence. Potential N-linked glycosylation sites
(*) on HA proteins and the cleavage sites between HA1 and HA2 subunits are marked. (B) Western blot analysis on the difference of susceptibility
to cleavage between H1 and H3 HA proteins expressed by different H1 and H3 HA DNA vaccine constructs in transiently transfected 293T cells.
(C) Western blot analysis on the secretion of H1 and H3 HA proteins by different H1 and H3 HA DNA vaccines in the lysate (L) or supernatant
(S) of transiently transfected 293T cells.
FIG. 4. Peak-level serum anti-HA IgG antibody responses in NZW rabbits at 2 weeks after the fourth DNA immunization induced by different
H1 and H3 HA DNA vaccines as measured by ELISA. Data shown are the geometric mean titers of each group, with standard deviations (error
bars) if applicable (three rabbits in each group), against either autologous or heterologous HA antigens.
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HA DNA vaccines, the full-length form of HA antigen elic-
ited much higher neutralizing antibody titers against the
autologous H1N1 virus A/NewCal/20/99 than did the mem-
brane-truncated form of HA antigen (Fig. 6A). The neutral-
izing antibody titers induced between these two forms of H1
HA antigens were also statistically different (P  0.05).
However, for H3 HA DNA vaccines, the difference in neu-
tralizing antibody titers between the full-length and TM-
truncated forms was much less when tested against the
H3N2 virus A/Moscow/10/99 (Fig. 6B). The neutralizing ac-
tivities were also highly serotype specific. Rabbit sera im-
munized with the H1 HA DNA vaccine neutralized only the
H1 virus, and rabbit sera immunized with the H3 HA DNA
vaccines neutralized mainly the H3 virus (Fig. 6).
Broad protective antibody responses induced by the bivalent
H1 plus H3 HA DNA vaccines. One advantage of DNA vacci-
nation is its ability to deliver multiple HA antigens in one
formulation. We next immunized rabbits with two bivalent HA
formulations. The bivalent 1 formulation included DNA vac-
cines expressing two TM-truncated HA inserts, H1-HA.dTM
and H3-HA.dTM. The bivalent 2 formulation included the
full-length H1-HA and TM-truncated H3-HA.dTM DNA vac-
cines. Both bivalent formulations were able to elicit compara-
ble anti-HA antibody responses recognizing various forms of
HA antigens of both H1 and H3 serotypes as confirmed by
ELISA and Western blot analyses (Fig. 7).
Although the HI titers of the two bivalent formulations
were similar against the H3 viruses (A/Panama/2007/99 and
A/Moscow/10/99), bivalent 2 formulation was more effective
than bivalent 1 formulation for generating HI antibodies
against the H1 virus (A/NewCal/20/99) (Fig. 8A). Similarly, the
neutralizing antibody results also confirmed that bivalent 2
formulation was able to elicit better neutralizing antibody re-
sponses than those of bivalent 1 formulation against the H1
virus (Fig. 8B). Because bivalent 2 formulation included the
full-length H1-HA DNA vaccine, these findings further con-
firmed that the full-length H1-HA antigen was able to elicit better
HI and neutralizing antibody responses than those of the H1-
HA.dTM antigen (Fig. 5 and 6). Therefore, in order to provide
the best protection against targeted viruses, the selection of an
optimal design for HA antigen is important for the development
of polyvalent influenza vaccines.
FIG. 5. The HI antibody responses in NZW rabbit sera immunized
with different designs of H1 and H3 HA DNA vaccines. The HI
antibody titers are shown as the geometric means for each group (three
rabbits per group), with standard deviations (error bars), against H1N1
(A/New Caledonia/20/99) and H3N2 (A/Panama/2007/99) viruses. The
statistical difference between each testing group was determined, and
the P value that was less than 0.05 is indicated.
FIG. 6. The NAb responses in NZW rabbit sera immunized with
different designs of H1 and H3 HA DNA vaccines. The NAb titers
against H1N1 (A/New Caledonia/20/99) or H3N2 (A/Moscow/10/99)
virus infection for MDCK cells are shown as the geometric means from
each group (three rabbits per group) with standard deviations (error
bars). The statistical difference between each testing group was deter-
mined, and the P value that was less than 0.05 is indicated.
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Data presented in this report proved that codon optimization
was effective for improving the antigen expression and immuno-
genicity of flu HA DNA vaccines. In early flu DNA vaccine
studies, there were only low or undetectable HA-specific antibody
responses after DNA immunizations. Positive antibody responses
were detected only after a flu virus challenge (9). In the last
several years, codon optimization has been shown effective for
improving the immunogenicity of DNA vaccines expressing hu-
man immunodeficiency virus antigens (1, 6, 10, 11, 41, 46, 54). In
addition, DNA vaccines with codon-optimized antigen gene in-
serts have been used successfully against viral (such as severe
acute respiratory syndrome) (53, 56), papillomaviral (3, 4, 20, 25),
bacterial (21, 47), and parasitic pathogens (17, 29). By using an
H1 serotype HA antigen as the model system in the current study,
we compared the relative levels of antigen expression and immu-
nogenicity between wild-type and codon-optimized flu HA DNA
vaccines in two animal models (mouse and rabbit) with two DNA
vaccine delivery methods (gene gun and intramuscular needle
injection). The data clearly demonstrated that the codon-opti-
mized HA DNA vaccines were able to induce better HA-specific
antibody responses than were the wild-type gene sequences be-
cause codon-optimized HA DNA vaccine was able to induce a
quicker rise and higher peak-level anti-HA antibody responses.
The ability of eliciting high-titer, anti-HA antibodies by
DNA immunization prior to the viral challenge allowed us to
expand our study to further measure the levels of protective
antibody components in animal sera immunized with HA an-
tigens from either H1 or H3 serotypes. Both high-level HI and
neutralizing activities were easily elicited by codon-optimized
DNA vaccines. The titers of protective antibodies achieved in
this report were not only significantly improved over that from
early versions of flu DNA vaccines (2, 9, 18, 22, 50) but also
comparable to or higher than those of positive anti-HA sera
reported in previous animal studies with various flu vaccines,
including recombinant viral vector-based flu HA vaccines (16,
30, 39) and inactivated and live flu vaccines (23, 38, 42).
FIG. 7. Levels and specificity of anti-HA IgG responses elicited by
bivalent HA DNA vaccines. (A) Peak serum-level anti-HA IgG re-
sponses in rabbits immunized with bivalent HA DNA vaccines (biva-
lent 1, H1-HA.dTM plus H3-HA.dTM, and bivalent 2, H1-HA plus
H3-HA.dTM) at 2 weeks after the fourth DNA immunization as mea-
sured by ELISA against the full-length H1-HA or H3-HA antigens.
Data shown are the geometric mean titers of each group (three rabbits
per group) with standard deviations (error bars). (B) Western blot
analysis of NZW rabbit sera immunized with either monovalent (H1-
HA.dTM or H3-HA.dTM) or bivalent formulations. The transmem-
brane-truncated HA proteins (H1-HA.dTM and H3-HA.dTM) or the
HA1 subunits of HA proteins (H1-HA1 and H3-HA1) expressed from
293T cells were used in the study.
FIG. 8. The HI and NAb responses induced by bivalent H1 plus H3
HA DNA vaccines. The statistical difference between each testing
group was determined, and the P values that are less than 0.05 are
indicated. (A) HI antibody responses are shown as the geometric mean
titers of each group (three rabbits per group), with standard deviations,
against either H1N1 (A/New Caledonia/20/99) or H3N2 (A/Panama/
2007/99) viruses. (B) NAb responses are shown as the geometric mean
titers of each group (three rabbits per group), with standard deviations
(error bars), against either H1N1 (A/New Caledonia/20/99) or H3N2
(A/Moscow/10/99) virus infection of MDCK cells.
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It is very interesting to discover that the protective antibody
responses were dependent on the forms of HA antigen inserts.
For the H1 HA antigen used in the current study, only the full-
length form was able to induce high levels of protective antibod-
ies, while both the full-length and the TM-truncated H1 HA
antigens elicited very similar levels of HA-specific binding anti-
body responses. Therefore the full-length H1 HA antigen was
more effective for preserving certain protective antigen confor-
mation than the TM-truncated form of H1 HA antigen was. On
the other hand, both the full-length and the TM-truncated forms
of H3 HA antigens were able to elicit similar levels of protective
antibodies. Singh et al. reported that the truncated anchor-free
HA could form monomers or trimers depending on the strain and
construct used (44). It is likely that the truncated H1 HA DNA
vaccine produces the monomeric forms, and truncated H3 HA
DNA vaccine produces the trimeric forms, which would contrib-
ute to the differences in conformation-sensitive protective anti-
body responses.
Consistent with the above finding that H1 serotype HA and H3
serotype HA antigens are conformationally different, we found
that the H1 HA antigen was resistant to natural cleavage into its
two subunits, while the H3 HA antigen was easily detected in the
forms of HA1 and HA2 subunits in transiently transfected 293T
cells. Treanor et al. conducted a recent vaccine study in humans
using a trivalent, baculovirus-expressed, recombinant HA vaccine
based on the HAs of influenza A/Panama/2007/99 (H3N2),
A/New Caledonia/20/99 (H1N1), and B/Hong Kong/330/2001
(52) and concluded that the H3 component, but not the H1 and
influenza virus type B components, elicited a robust neutralizing
antibody response in humans. Although the authors could not
explain the reasons for these differences, their results are in agree-
ment with our study, in which we found that H1 HA-based vac-
cines are less immunogenic when lacking the appropriate trans-
membrane and cytoplasmic domains.
Our results will have an important impact on the selection
and design of HA antigens for developing the most protective
flu vaccines. Traditionally, in order to study the structure re-
quirement for immunogenicity and protection by individual
HA antigens, the flu viral stocks expressing different HA an-
tigens in their native or modified forms would have to be
produced, inactivated, concentrated, and purified. This process
was shown in a recent effort studying the role of specific HA
amino acids in the immunogenicity and protection of H5N1
influenza virus vaccines (13). Such a process is complicated and
may introduce multiple variables to the final immunization
studies. There has been a limited effort to produce HA anti-
gens by a recombinant protein approach, presumably due to
the challenges of cost and time when facing the large number
of HA antigens existing in the world, as the results of antigen
drift, even within one serotype of flu viruses. The discovery of
DNA immunization technology in the early 1990s initially led
to high enthusiasm that this novel approach may be a simple
alternative to the traditional flu vaccines. However, the low
immunogenicity of early DNA vaccine designs, especially in
higher animal species or humans when delivered without the
help of physical delivery methods (gene gun or electropora-
tion), quickly dampened such hope. One important early ob-
servation was that flu DNA vaccines were unable to elicit
high-level, HA-specific antibody responses prior to viral chal-
lenge (9). In the last decade, significant improvement has been
made in DNA vaccination approaches. However, such im-
provement has not been well incorporated into flu vaccine
applications. Data presented in this report confirmed that
codon optimization was effective for improving the immuno-
genicity of HA DNA vaccines. With a codon-optimized DNA
vaccination approach, including the use of the gene gun deliv-
ery method, we report here that it is feasible to reliably elicit
high-level protective antibody responses against flu HA anti-
gens. This will provide a powerful tool to greatly accelerate the
identification, selection, and rational design of the most pro-
tective HA antigens, which can then be incorporated into ei-
ther conventional or novel flu vaccine strategies in either wild-
type or codon-optimized gene sequences.
The development of high-immunogenicity HA DNA vac-
cines also provides an alternative approach to the development
of vaccines against pandemic influenza caused by avian flu
viruses since these emerging flu viruses do not grow well
enough to produce high-yield viral stocks for the manufactur-
ing of inactivated vaccines. Recent HA DNA vaccine studies in
humans have demonstrated that significant levels of HA-spe-
cific antibody responses are induced when such DNA vaccines
are delivered by a gene gun (7). With DNA vaccination, it is
easy to mix several protective antigens in one delivery. Our
data with HA antigens from both H1 and H3 serotypes con-
firmed that, relative to monovalent antigen formulation, such
polyvalent formulations can be equally effective in eliciting
protective antibody responses.
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